drugset / Trial / NCT03827655

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

NCT03827655

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery. Participants will be treated with TAK-954 before surgery and up to 10 days after surgery.

Timeline

Start
2019-03-07
Primary completion
2022-05-27
Completion
2022-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject felcisetrag Small molecule 0.001 mg/ml Intravenous
Subject felcisetrag Small molecule 0.005 mg/ml Intravenous